Finch Therapeutics Group, Inc.: insider trades · United States · SEC (Form 4)

About Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. is a U.S.-based biotechnology company whose strategic center of gravity has shifted decisively toward microbiome intellectual property monetization. Historically listed on NASDAQ in the United States, the company announced delisting and SEC deregistration steps in 2024, and its corporate footprint is now best understood as a lean IP-and-asset platform rather than a conventional development-stage biopharma. Its headquarters is in the Boston/Somerville, Massachusetts area, reflecting its roots in the Greater Boston life sciences ecosystem. Finch was formed in 2014, emerging from academic and translational microbiome work connected to MIT, OpenBiome, and other early pioneers in fecal microbiota transplantation and microbiome science. The company later merged with Crestovo to build a more integrated microbiome therapeutics platform. Its original operating model was built around Human-First Discovery®, a proprietary approach designed to reverse-engineer successful clinical experience in microbiome transplantation and identify disease states linked to microbiome disruption. That platform supported the development of orally administered microbiome therapeutics for serious unmet medical needs. The best-known asset in Finch’s history was CP101, an investigational oral microbiome candidate intended to help prevent recurrent Clostridioides difficile infection. The program generated positive phase 2 data, but Finch discontinued its phase 3 trial in January 2023 and subsequently pivoted away from active late-stage clinical development. Today, the company’s principal business lines are much narrower: realizing value from its intellectual property estate, licensing microbiome technology to collaboration partners, enforcing patent rights when appropriate, and, in selected cases, generating additional data on targeted assets through academic collaborations. Finch says it has built a substantial patent portfolio, including more than 70 issued U.S. and foreign patents with relevance across both donor-derived and donor-independent microbiome therapeutics. That matters competitively because microbiome therapeutics remain a scientifically attractive but crowded and still-developing area, where defensible IP, translational know-how, and data quality are key differentiators. Finch’s competitive position is therefore not that of a scaled commercial drugmaker, but of a specialized intellectual-property holder with optionality around licensing, partnerships, and litigation-driven value recovery. Recent corporate developments have reinforced that repositioning. The company has stated that it does not currently expect to advance any product candidate through clinical trials or commercial approval, nor does it expect revenue from product sales. In January 2025, Finch announced the resignation of its CFO, and in 2024 it disclosed delisting from NASDAQ and SEC deregistration actions. For investors, Finch should be viewed as a restructuring-stage U.S. biotech with a microbiome heritage, a patent-driven value proposition, and limited near-term operating visibility.